1. Home
  2. ARBE vs RFL Comparison

ARBE vs RFL Comparison

Compare ARBE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

HOLD

Current Price

$0.76

Market Cap

79.1M

Sector

Technology

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.30

Market Cap

63.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARBE
RFL
Founded
2015
2017
Country
Israel
United States
Employees
144
N/A
Industry
EDP Services
Real Estate
Sector
Technology
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
63.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ARBE
RFL
Price
$0.76
$1.30
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$2.38
N/A
AVG Volume (30 Days)
985.5K
46.9K
Earning Date
05-19-2026
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
$363.94
N/A
Revenue Next Year
$286.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.55
$1.12
52 Week High
$2.88
$3.19

Technical Indicators

Market Signals
Indicator
ARBE
RFL
Relative Strength Index (RSI) 51.03 58.70
Support Level $0.76 $1.30
Resistance Level $1.46 $1.34
Average True Range (ATR) 0.05 0.08
MACD 0.02 0.01
Stochastic Oscillator 50.04 86.49

Price Performance

Historical Comparison
ARBE
RFL

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: